Background: Patient satisfaction is used as one of the measurements for quality of health care services and it has been related with how quality of communication between physicians and patients is perceived.The aim of this study is to to describe differences between parents and health care providers in perception of the medical information given by doctors to parents.
Medical information
Parents (nϭ97) Health care providers (nϭ98) P value Characteristics F-up clinic(nϭ18) Phone (nϭ56) NICU(nϭ23) Doctors(nϭ25) Nurses(nϭ73) Quantity 8 (8-10) 8 (7-10) 8 (6-10) 8 (7-8) 6 (5-8)
[it]0.001 Quality 8 (8-10) 8 (7-9) 8 (6-10) 7 (6-8) 6 (5-7)
[it]0.001 Understandable 9.5 (8-10) 9(7.5-10) 8 (6-10) 7 (7-9) 5 (3-7)
[it]0.001 Concealment 1(0-2.5) 0 (0-3) 1 (0-7) 3 (2-6) 6 (3-7)
[it]0.001
P value: statistical differences between parents and health care providers
Conclusion: Medical information provided to parents whose baby has been admitted to a NICU seems satisfactory in scope and quality. Parents assessment is consistently more favourable than health care providers. Among parents, those with a baby still admitted to the NICU show a slightly less favourable perception. Nurses assessment of medical information is clearly more unfavourable than parents or doctors for most of the items. Background: Perinatal asphyxia (PA) accounts for the majority of developmental and cognitive deficits. Various therapeutic interventions after hypoxia-ischemia (HI) have been shown to reduce brain injury in the short-term perspective, although long-term functional and structural improvements are still uncertain. Objective: The aim of this study was to evaluate the neuroprotective efficiency of erythropoietin (EPO), N-acetylcysteine (NAC) and their combination after neonatal HI with respect to long term (neuropathology and sensorimotor function) outcome.
COMBINATION THERAPY WITH ERYTHROPOIETIN AND N-ACETYLCYSTEINE PRO-VIDES PRONOUNCED IMPROVEMENT OF LONG LASTING SENSORIMOTOR AND NEUROPATHOLOGICAL DISTURBANCES FOLLOWING PERINATAL ASPHYXIA IN RATS
Methods: 7 days old rats were separated into 5 groups: A (control), neither ligated nor exposed to hypoxia, B (HI) ligated and exposed to hypoxia, C, D and E ligated, exposed to hypoxia and treated respectively with NAC (100mg/kg), EPO (2000 U/kg) and their combination. At the age of 42 days, the behavior of the rats was evaluated through 5 sensorimotor tests. Muscle power, motor coordination, reflexes and limb placing (LP) were tested to different sensory stimulations. The sensorimotor tests lasted six days. The study was completed with the evaluation of brain tissue damages at the age of 48 days.
Results: In all the separate tests the HI rats performed significantly worse than the control and treated rats (table). In particular the differences between the groups in the grip traction, postural reflex and limb placing task were more pronounced compared to other tests (table) . Neonatal HI resulted in extensive neuronal damage that was significantly limited after treatment.
Control (8)
HI ( Conclusion: HI brain damage during the neonatal period resulted in long-term disorders in motor coordination, muscle power and the reaction of the limbs to sensory stimuli. EPO and NAC attenuated the effects of HI on the neonatal brain by reducing the progression of neuronal injury and improving sensorimotor function. However their combination resulted in more pronounced functional improvement. Behavioral alterations represent a useful endpoint for studying the consequences of a perinatal HI insult and the efficacy of potential neuroprotective treatments. Background: Anderson-Fabry disease (FD) is an X-linked lysosomal storage disorder which also affects female carriers and has an early onset of symptoms in childhood in both genders. Signs and symptoms are frequently misunderstood and often diagnosis is made approximately 10 -20 years after their onset. This has been clearly demonstrated by Fabry outcome survey (FOS) a European database on the natural history of FD and the effects of enzyme replacement therapy with agalsidase alfa (Replagal).
DIAGNOSIS OF ANDERSON-FABRY DISEASE IN CHILDHOOD. WHAT SHOULD WE FOCUS ON?
Methods: Demographic data on 82 children (40 boys and 42 girls) below 18 years of age, with a median age at FOS entry of 12.9 (0.7-17.9) were analysed Results: Most frequently reported symptoms (60 -80%) were neurological and gastrointestinal including altered temperature sensitivity, pain, acroparaesthesiae, dyshydrosis, abdominal pain and altered bowel habits. Over 40% had auditory (tinnitus, vertigo), and dermatological (angiokeratoma) symptoms. Median age at onset of symptoms was 6 years whilst median age at diagnosis was 10 years (figure).
Conclusion:
Data in FOS show that also the selected group of paediatric patients has a consistent delay of diagnosis. As ERT is licensed for use in FD and could potentially delay or prevent the onset of life-threatening complications of FD seen in adults, early diagnosis is important. Emphasis is therefore to have a heightened awareness of the clinical presentation of childhood FD, especially when they present with an unusual constellation of symptoms including pain, dyshydrosis, abdominal pain and tinnitus. Background: The decisition to treat systemic hypotension in LBWI is based on the belief of keeping adecuate organ perfusion. However, the impact of vasopressor treatment on cerebral tissue perfusion has not been systematically evaluated on the basis of a controlled clinical trial. Aims: To explore the effects on brain hemodynamics of two inotropes used to treat hypotension in LBWI.
CARDIOVASCULAR SUPPORT IN LOW BIRTH WEIGHT INFANTS AND CEREBRAL HEMODYNAMICS: A RANDOMIZED BLINDED CLINICAL TRIAL
Methods: Newborns Ͻ1501g BW or Ͻ31 wk GA, with mean blood pressure (MAP) h, were randomly assigned to DP (2.5, 5, 7.5, 10 g/K/min) (nϭ27) or EP (0.125, 0.250, 0.375, 0.5 g/K/min) (nϭ32), increased in stepwise fashion every 20 min until the desired MAP (MAP-OP) was attained and maintained. Outcome measures: Quantitative changes in cerebral concentrations of oxyhemoglobin (HbO) and deoxyhemoglobin (HbR), cerebral intravascular oxygenation (Ä HbD) that is Ä (HbO-HbR), and cerebral blood volume (Ä CBV), were assesed by near infrared spectroscopy. Simultaneous MAP, heart rate (HR), trascutaneous PCO2/PO2 and peripheral oxygen saturation were continuously recorded and stored for latter analysis at: baseline (BL), at 20 min after each increase in dose (T1, T2, T3 and T4) until MAP-OP was reached, and then every 20 min up to 1 h of stable MAP-OP (60-OP).
Results: BW and GA were 974Ϯ282 g and 27.9Ϯ2.3 wk, respectively. The studies were performed at a mean age of 5.3Ϯ3.7 hours of life. MAP-OP was achieved at: T1 DP 22.2%, EP 18.8%; T2 DP 33.3%, EP 28.1%; T3 DP 25.9%, EP 18.8%; T4 DP 14.8%, EP 28.1%. No differences were found in the rate of treatment failure (DP 3.7%, EP 6.3%). There was a significant linear increase in MAP, HR and Ä CBV from BL throughout the study period (pϽ0.001) without differences between the groups except for HR (higher in EP at MAP-OP and 60-OP, pϽ0.01). The increase in Ä CBV was coupled with a significant increase in Ä HbD. Changes in MAP were significantly correlated with Ä HbD at MAP-OP and at 60-OP. PCO2 and PO2 values remained unvaried. The effect of drug-dose escalation showed no differences in the variables' behaviour except for a higher HR in EP from 20 min after dose 2 (T2) and onwards (pϽ0.05 at T2). Drug-induced changes in cerebral hemodynamics varied according to GA.
Conclusion: In hypotensive LBWI cardiovascular support with low-moderate dose DP or low-dose EP improve cerebral perfusion, as indicated by the increase in both Ä CBV and Ä HbD. Low-dose EP is as effective as low-moderate dose DP to increase MAP in LBWI. Helsinki, Pediatrics, Helsinki, Finland; 3 University Of Kuopio, Pediatrics, Kuopio, Finland Background: Lung inflammation and early adrenal insufficiency are major risk factors of BPD in very low birth weight infants. Early low-dose hydrocortisone treatment may effectively prevent BPD with fewer side effects than early dexamethasone (Pediatrics. 1999; 104:1258) . Objectives: To study whether a low-dose hydrocortisone (HC) prevents BPD without acute side effects, and to evaluate serum cortisol levels before and after the supplementation.
RANDOMIZED, CONTROLLED TRIAL ON EARLY LOW-DOSE HYDROCORTISONE TREATMENT FOR PREVENTION OF BRONCHOPULMONARY DYSPLASIA (BPD)
Methods: The study was multicenter, randomized placebo-controlled blinded trial. Infants weighing 501-1250 g with gestation age Ͻ30 weeks and with respiratory failure were eligible before 36 hours of age. HC or placebo was given for 10 days as follows: HC 2.0 mg/kg/d for 2 days, 1.5 mg/kg/d for 2 days and 0.75 mg/kg/d for 6 days. ACTH test was done at the onset of study and one day after the intervention (Synacthen dose 0.1 ug/kg: serum cortisol levels evaluated before and at 30 min). Primary outcome was survival without BPD at the age of 36 gestational weeks.
Results: The study was discontinued after 51 infants were enrolled as a consequence of increased risk of gastrointestinal (GI) perforations in the HC group (17% vs. 0%, pϭ0.04). Survival without BPD tended to be higher (55% vs. 45%, OR 1.76, 95% CI 0.52-5.91) and patent ductus arteriosus significantly decreased in the HC group (40% vs. 73%, OR 0.25, 95% CI 0.08 -0.80). There were no differences between the study groups in the growth pattern until 36 weeks of gestation. The subgroup of infants with normal ACTH response (delta cortisol Ͼ 100 nmol/l) at the onset of the study had high risk of GI-perforations during HC (3/8 vs. 0/9, pϭ0.04). In this subgroup there was no difference in the incidence of BPD between the HC and placebo groups (2/8 vs. 2/9 OR 1.17, 95% CI 0.12-10.99). Among infants with impaired adrenal function (delta cortisol Ͻ 100 nmol/l) at birth, HC appeared to decrease the odds of BPD (2/10 vs. 6/9, OR 0.13, 95% CI 0.02-0.99). There were no GI-perforations in this subgroup.
Conclusion: Early low-dose hydrocortisone increases the risk of gastrointestinal perforations among VLBW infants who respond normally to ACTH at birth. The subgroup of infants with impaired early adrenal function benefited from HC treatment without GI-perforations. Further studies are required to define the indications of hydrocortisone for prevention of BPD.
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